Because EBV-negative NPC lacks viral oncoprotein–driven Nrf2 activation, the GPX4-stabilizing mechanism described here is largely restricted to EBV-positive disease. This evidence concerns the gene NFE2L2 and nasopharyngeal carcinoma.